**Title: Glutamate Transport: A new bench to bedside mechanism for treating drug abuse**

**Abstract**

Glutamate transmission in cortical synapses into the basal ganglia, in particular into the nucleus accumbens, are markedly altered by addictive drugs. A primary alteration seen after withdrawal from all addictive drugs in self-administration animal models of addiction is a reduction in the elimination of glutamate that is released from these synapses. Specifically, there is a reduction in the glial glutamate transporter EAAT2. As a result of reduced EAAT2 the fidelity of cortico-accumbens transmission is corrupted such that when an animal trained to associate a cue with drug delivery is shown that cue in the absence of drug, the cue is highly motivating to seek the drug. This level of motivation is associated with a number of transient changes in the cortico-accumbens synapses that collectively indicate that the synapses are transiently potentiated (t-SP). Importantly, the same self-administration protocol for a natural reward such as sucrose pellets does not alter EAAT2, nor is cue-induced sucrose seeking associated with t-SP. After a brief description of the cortico-accumbens neuropathology that appears to contribute to relapse in animal models of addiction, we will discuss the success we and other have had at inhibiting relapse in animal models by pharmacologically restoring EAAT2. In the preclinical literature, restoration of EAAT2 can be accomplished by repeated administration of a number of compounds, including N-acetylcysteine (NAC) and ceftriaxone. However, because NAC is orally active and has a long record of clinical use for acetaminophen overdose and as a mucolytic agent in cystic fibrosis, we and others have examined NAC in clinical trials for treating addiction and other neuropsychiatric diseases that are characterized in part by symptoms of intrusive thinking. Here, I will highlight recent trials with marijuana and cocaine addicts, as well as patients co-morbid for post-traumatic stress disorder (PTSD) and substance use disorder. In these studies, NAC was at least partly effective at reducing craving, relapse and/or criteria for a diagnosis of PTSD. Finally, I will discuss aspects of the various trials that point to how NAC may be most effectively employed clinically in combination with psychosocial interventions, and perhaps other pharmacological treatments.
